Mogamulizumab is a humanized antibody targeting CC chemokine receptor 4 (CCR4). This
post‐marketing surveillance was conducted in Japan as a regulatory requirement from 2014 …

Objectives; T-cell lymphomas generally have a poor outcome with shorter long-term survival
compared with B-cell lymphomas. CC chemokine receptor 4 (CCR4) is highly expressed by …

Background CC chemokine receptor 4 (CCR4) is the receptor for macrophage-derived
chemokine (MDC/CCL22) and thymus activation-regulated chemokine (TARC/CCL17) …

Abstract Abstract 795 Background: Mogamulizumab (KW-0761) is a humanized anti-CCR4
antibody engineered to exert potent ADCC by defucosylation. In a phase I study for patients …

Purpose CC chemokine receptor 4 (CCR4) is expressed by peripheral T-cell lymphomas
(PTCLs) and is associated with poor outcomes. Mogamulizumab (KW-0761) is a …

Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal
antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising …

Objective This prospective, observational, postmarketing surveillance was conducted to
evaluate the safety and effectiveness of mogamulizumab, an anti‐CC chemokine receptor 4 …

Background: CTCL represents a rare group of non-Hodgkin lymphomas with substantial
negative impact on patient (pt) quality of life and mortality in advanced-stage disease …

Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, dosing, and
administration of mogamulizumab for the treatment of T-cell lymphomas. Data Sources: A …

Simple Summary Mogamulizumab is a recent monoclonal antibody prescribed in the second
line to treat advanced mycosis fungoides and Sézary syndromes. We collected data from all …